Skip to content
sellModerate cluster of 310b5-1 plan

Jeffrey Dierks sold $1.1M of HRMY

CHIEF COMMERCIAL OFFICER at Harmony Biosciences Holdings, Inc.. 30,598 shares at an average of $37.51, traded Jan 16, 2025, filed Jan 21, 2025.

Warning score
40
Value
$1.1M
30,598 shares
Holdings after
0
-104% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $1.1M at market
    +25
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -13.8%, 3m -27.9%, 6m -9.3%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HRMYOct 9, 2026 · close 40.28
Since filing Jan 21, 2025: -0.4%SPY +31.6% · excess -32.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-001825, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 16, 2025MOption exercise
Common Stock10b5-1
+29,475$33.44$986k29,475Jan 21, 2025
Jan 16, 2025SOpen-market sale
Common Stock10b5-1
-29,475$37.41$1.1M0Jan 21, 2025
Jan 21, 2025MOption exercise
Common Stock10b5-1
+1,123$33.44$38k1,123Jan 21, 2025
Jan 21, 2025SOpen-market sale
Common Stock10b5-1
-1,123$40.00$45k0Jan 21, 2025
Jan 16, 2025MOption exercise
Stock Optionderivative10b5-1
-29,475$0.00$06,738Jan 21, 2025
Jan 21, 2025MOption exercise
Stock Optionderivative10b5-1
-1,123$0.00$05,615Jan 21, 2025

Related signals

Other insiders at Harmony Biosciences Holdings, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
25Weak
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Kumar Budur
CHIEF MEDICAL OFFICER
$1.7M
38,452 shares
-258%
25Weak
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Kumar Budur
CHIEF MEDICAL OFFICER
$1.5M
33,954 shares
-141%
18Weak
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Sandip Kapadia
CHIEF FINANCIAL OFFICER
$139k
3,746 shares
-13%
44Moderate
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Sandip Kapadia
CHIEF FINANCIAL OFFICER
$753k
20,961 shares
-100%
43Moderate
HRMYsell 210b5-1
Harmony Biosciences Holdings, Inc.
Jeffrey M. Dayno
PRESIDENT, CEO
$1.0M
25,933 shares
-130%
37Weak
HRMYsell 210b5-1
Harmony Biosciences Holdings, Inc.
Sandip Kapadia
CHIEF FINANCIAL OFFICER
$791k
20,000 shares
-100%
32Weak
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Sandip Kapadia
CHIEF FINANCIAL OFFICER
$120k
3,427 shares
-100%
44Moderate
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Sandip Kapadia
CHIEF FINANCIAL OFFICER
$787k
21,573 shares
-100%
35Weak
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Sandip Kapadia
CHIEF FINANCIAL OFFICER
$227k
6,987 shares
-100%
11Weak
HRMYsell10b5-1
Harmony Biosciences Holdings, Inc.
Jeffrey Dierks
CHIEF COMMERCIAL OFFICER
$159k
4,869 shares
-100%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.